SELLAS Life Sciences Group Inc buy Wolf_of_WS
Start price
05.03.23
/
50%
€1.52
Target price
05.03.24
-
Performance (%)
-19.55%
End price
17.03.23
€1.22
Summary
This prediction ended on 17.03.23 with a price of €1.22. The prediction for SELLAS Life Sciences Group Inc disappointed with a performance of -19.55%. Wolf_of_WS has 50% into this predictionSELLAS Life Sciences is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, is a cancer immunotherapy being developed for the treatment of acute myeloid leukemia (AML) and ovarian cancer. SELLAS Life Sciences is listed on the NASDAQ stock exchange under the symbol RXII.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| SELLAS Life Sciences Group Inc | 6.181% | 6.181% | -13.548% |
| iShares Core DAX® | -0.268% | 5.471% | 14.271% |
| iShares Nasdaq 100 | 1.854% | 7.851% | 35.426% |
| iShares Nikkei 225® | 0.284% | 1.729% | 9.943% |
| iShares S&P 500 | 1.178% | 5.269% | 27.989% |
Comments by Wolf_of_WS for this prediction
In the thread SELLAS Life Sciences Group Inc diskutieren
Buy SELLAS Life Sciences Group Inc